AZ says recovery to continue to despite patent expiry and Br...

AstraZeneca has upped its revenue expectations following a strong second quarter, saying that sales of newer drugs will offset a major patent expiry and the impact of Brexit.

More woe for Roche as another Rituxan biosimilar approved in...

The FDA has approved a second biosimilar of Roche’s leukaemia drug Rituxan, along with yet another biosimilar of AbbVie’s inflammatory diseases blockbuster Humira.

EMA starts review of Xtandi in hormone-sensitive prostate ca...

Roche under pressure in US as Amgen/Allergan launch US cance...

Amgen and Allergan have launched their cut-price biosimilar competitors to two big-selling cancer drugs from Roche in the US.

Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPO

NICE changes its mind on Novartis’ Kisqali for breast cancer